Neuraxis, Inc. (NRXS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neuraxis, Inc. (NRXS) has a cash flow conversion efficiency ratio of -0.214x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.23 Million) by net assets ($5.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Neuraxis, Inc. stock valuation for the company's overall valuation and market capitalisation.
Neuraxis, Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Neuraxis, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neuraxis, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuraxis, Inc. ranked by their cash flow conversion efficiency. See NRXS debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rand Mining Ltd
AU:RND
|
0.048x |
|
Jinro Distillers Co. Ltd
KQ:018120
|
0.107x |
|
Western Energy Services Corp.
TO:WRG
|
0.027x |
|
Shemen Industries Ltd
TA:SMNIN
|
-0.015x |
|
Tah Kong Chemical Industrial
TWO:4706
|
0.003x |
|
Tongyang
KO:001520
|
0.020x |
|
Choppies Enterprises Ltd
JSE:CHP
|
0.910x |
|
Kyungin Synthe
KO:012610
|
0.066x |
Annual Cash Flow Conversion Efficiency for Neuraxis, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Neuraxis, Inc. from 2020 to 2025. View Neuraxis, Inc. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.40 Million | $-6.43 Million | -1.892x | +35.84% |
| 2024-12-31 | $2.07 Million | $-6.10 Million | -2.949x | -161.82% |
| 2023-12-31 | $-1.40 Million | $-6.69 Million | 4.770x | +1057.01% |
| 2022-12-31 | $-5.57 Million | $-2.30 Million | 0.412x | -84.76% |
| 2021-12-31 | $-825.66K | $-2.23 Million | 2.706x | +207.46% |
| 2020-12-31 | $1.64 Million | $-4.14 Million | -2.518x | -- |
About Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional … Read more